Evidence map›Paper›PMID 39257750›Full record

ArticlebioRxiv : the preprint server for biology2024

CHCHD2 mutant mice display mitochondrial protein accumulation and disrupted energy metabolism.

Szu-Chi Liao, Kohei Kano, Sadhna Phanse, Mai Nguyen, Elyssa Margolis, YuHong Fu, Jonathan Meng, Mohamed Taha Moutaoufik, Zac Chatterton, Hiroyuki Aoki and 10 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Szu-Chi LiaoGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0003-2744-363X
Kohei KanoGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-0223-5781
Sadhna PhanseDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.ORCID 0000-0001-6306-0551
Mai NguyenGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0003-3550-7728
Elyssa MargolisWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA.ORCID 0000-0001-8777-302X
YuHong FuAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD.ORCID 0000-0003-4539-2039
Jonathan MengGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-4315-3483
Mohamed Taha MoutaoufikDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.ORCID 0000-0002-2013-1601
Zac ChattertonAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD.ORCID 0000-0002-6683-1400
Hiroyuki AokiDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.ORCID 0009-0005-9143-086X
Jeffrey SimmsGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA.
Ivy HsiehDepartment of Pathology, University of California San Francisco, San Francisco, CA.
Felecia SutejaAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD.
Yoshitaka SeiGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-4725-8725
Eric J HuangWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, CA.ORCID 0000-0002-5381-3801
Kevin McAvoyFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY.ORCID 0000-0002-0025-1921
Giovanni ManfrediFeil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY.ORCID 0000-0003-3893-1348
Glenda HallidayAligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD.ORCID 0000-0003-0422-8398
Mohan BabuDepartment of Biochemistry, University of Regina, Regina, Saskatchewan, Canada.ORCID 0000-0003-4118-6406
Ken NakamuraGladstone Institute of Neurological Disease, Gladstone Institutes, San Francisco, CA.ORCID 0000-0002-9192-182X

Funding

UCSF IRACDA Scholars ProgramK12GM081266 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Raymond M. Esquerra, HOLLY A. INGRAHAM · 2007 to 2026
$19.4M
Mitochondrial Integrated Stress Response in Neurological DiseasesR35NS122209 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Giovanni Manfredi · 2021 to 2026
$6.6M
Defining Strategies to Target Energy Failure in Metabolically Vulnerable Human CellsR01AG065428 · NIA · J. DAVID GLADSTONE INSTITUTES · PI NAKAMURA, KEN · 2020 to 2024
$3.7M
Understand and probing disrupted glucose metabolism in Alzheimer's diseaseRF1AG064170 · NIA · J. DAVID GLADSTONE INSTITUTES · PI CHAUMEIL, MYRIAM MARIANNE, NAKAMURA, KEN · 2019 to 2019
$3.6M
EXTRAMULAR RESEARCH FACILITIES CONSTRUCTIONC06RR018928 · NCRR · J. DAVID GLADSTONE INSTITUTES · PI MAHLEY, ROBERT W. · 2003 to 2003
$2.1M
Understanding how neuronal glucose metabolism changes in AD due to ApoE4F32AG082460 · NIA · J. DAVID GLADSTONE INSTITUTES · PI SEI, YOSHI · 2023 to 2025
$240k
NCRR NIH HHS C06 RR018928NIA NIH HHS F32 AG082460NIA NIH HHS R01 AG065428NIA NIH HHS RF1 AG064170NIGMS NIH HHS K12 GM081266NINDS NIH HHS R35 NS122209
6 · The paper itself

Abstract

Mutations in the mitochondrial cristae protein CHCHD2 lead to a late-onset autosomal dominant form of Parkinson's disease (PD) which closely resembles idiopathic PD, providing the opportunity to gain new insights into the mechanisms of mitochondrial dysfunction contributing to PD. To begin to address this, we used CRISPR genome-editing to generate CHCHD2 T61I point mutant mice. CHCHD2 T61I mice had normal viability, and had only subtle motor deficits with no signs of premature dopaminergic (DA) neuron degeneration. Nonetheless, CHCHD2 T61I mice exhibited robust molecular changes in the brain including increased CHCHD2 insolubility, accumulation of CHCHD2 protein preferentially in the substantia nigra (SN), and elevated levels of α-synuclein. Metabolic analyses revealed an increase in glucose metabolism through glycolysis relative to the TCA cycle with increased respiratory exchange ratio, and immune-electron microscopy revelated disrupted mitochondria in DA neurons. Moreover, spatial genomics revealed decreased expression of mitochondrial complex I and III respiratory chain proteins, while proteomics revealed increased respiratory chain and other mitochondrial protein-protein interactions. As such, the CHCHD2 T61I point-mutation mice exhibit robust mitochondrial disruption and a consequent metabolic shift towards glycolysis. These findings thus establish CHCHD2 T61I mice as a new model for mitochondrial-based PD, and implicate disrupted respiratory chain function as a likely causative driver.

Identifiers

PMID39257750
PMCPMC11384018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.